Lexeo Therapeutics News

Lexeo Therapeutics(LXEO.US) Officer Sells US$66,093 in Common Stock

$Lexeo Therapeutics(LXEO.US)$ Officer Townsend Richard Nolan sold 5,000 shares of common stock on May 13, 2024 at an average price of $13.2186 for a total value of $66,093.Source: Announcement What is

Futu NewsMay 14 15:52

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)

TipRanksMay 14 03:40

Lexeo Therapeutics | 10-Q: Quarterly report

SEC announcementMay 9 06:07 · Announcements

Lexeo Therapeutics 1Q Research and Developement Expenses $15.7M >LXEO

Lexeo Therapeutics 1Q Research and Developement Expenses $15.7M >LXEO

Dow JonesMay 9 06:03

Lexeo Therapeutics 1Q Loss/Shr 77c >LXEO

Lexeo Therapeutics 1Q Loss/Shr 77c >LXEO

Dow JonesMay 9 06:02

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and

GlobeNewswireMay 7 06:30

Buy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy Advancements

TipRanksApr 26 01:07

Bernard Davitian to Exit Board of Lexeo Therapeutics

Lexeo Therapeutics, Inc. (LXEO) has issued an update.

TipRanksApr 22 07:22

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics, Inc. (Nasdaq: LXEO) today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.

GlobeNewswireApr 22 06:30

Lexeo Therapeutics Granted FDA Fast Track Designation For LX2006, AAV-Based Gene Therapy Candidate For The Treatment Of Friedreich's Ataxia Cardiomyopathy

Lexeo Therapeutics Granted FDA Fast Track Designation For LX2006, AAV-Based Gene Therapy Candidate For The Treatment Of Friedreich's Ataxia Cardiomyopathy

BenzingaApr 16 06:31

Lexeo Therapeutics Files to Sell 6.97M Shares of Common Stock for Holders

Seeking AlphaApr 9 08:02

Stifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

TipRanksMar 13 21:05

Lexeo Therapeutics Raises $95 Million Via Private Placement of Shares

Lexeo Therapeutics (LXEO) said Wednesday it sold 6.3 million common shares in a private placement at $15.13 each, for gross proceeds of $95 million. The company said it plans to use the net proceeds t

MT NewswiresMar 13 16:54

Press Release: Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with p

Dow JonesMar 13 15:22

Optimistic Outlook for Lexeo Therapeutics With Strong Clinical and Financial Performance Justifying Buy Rating

TipRanksMar 13 00:55

Lexeo Therapeutics Is Maintained at Outperform by RBC Capital

Lexeo Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesMar 12 10:39

Lexeo Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/12/2024 59.15% RBC Capital $22 → $24 Maintains Outperform 11/28/2023 52.52% Chardan Capital → $23 Initi

BenzingaMar 12 10:27

RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept

Lexeo Therapeutics (LXEO) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $19 to $24. Price: 14.22, Change: -0.27, Percent Change: -1.86

MT NewswiresMar 12 06:53

RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)

TipRanksMar 12 05:45

Lexeo Therapeutics' Strategic $95M Share Placement and Financial Update

TipRanksMar 11 15:22